drugset / Trial / NCT00728533
Open-Label, Randomised Parallel-Group Study
RandomizedParallel-groupOpen-labelTreatment
Summary
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 360 mg | — |
| Subject | Degarelix | Other / unclassified | 480 mg | — |